DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment Meeting Abstract
| Authors: | Kortüm, M.; Lee, H. C.; Cohen, A. D.; Chari, A.; Hultcrantz, M.; Nooka, A. K.; Callander, N.; Suvannasankha, A.; Badros, A.; Libby, E.; Trudel, S.; Richardson, P.; Sborov, D.; Rodriguez Otero, P.; Lonial, S.; Zhi, E.; Lewis, E.; Gupta, I.; Opalinska, J. |
| Abstract Title: | DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment |
| Meeting Title: | 2020 Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (DGHO) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 43 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Oct 9-11 |
| Meeting Location: | Virtual |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2020-10-01 |
| Start Page: | 102 |
| Language: | English |
| ACCESSION: | WOS:000575955000238 |
| PROVIDER: | wos |
| DOI: | 10.1159/000510995 |
| Notes: | Meeting Abstract: 204 -- "2020 Virtual Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology" -- Source: Wos |
